Historical Valuation
IGC Pharma Inc (IGC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 30.54 is considered Overvalued compared with the five-year average of -1.62. The fair price of IGC Pharma Inc (IGC) is between 0.16 to 0.27 according to relative valuation methord. Compared to the current price of 0.30 USD , IGC Pharma Inc is Overvalued By 11.14%.
Relative Value
Fair Zone
0.16-0.27
Current Price：0.30
11.14%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
IGC Pharma Inc (IGC) has a current Price-to-Book (P/B) ratio of 3.31. Compared to its 3-year average P/B ratio of 3.03 , the current P/B ratio is approximately 9.17% higher. Relative to its 5-year average P/B ratio of 2.59, the current P/B ratio is about 27.77% higher. IGC Pharma Inc (IGC) has a Forward Free Cash Flow (FCF) yield of approximately -20.82%. Compared to its 3-year average FCF yield of -24.95%, the current FCF yield is approximately -16.58% lower. Relative to its 5-year average FCF yield of -23.35% , the current FCF yield is about -10.82% lower.
P/B
Median3y
3.03
Median5y
2.59
FCF Yield
Median3y
-24.95
Median5y
-23.35
Competitors Valuation Multiple
AI Analysis for IGC
The average P/S ratio for IGC competitors is 16.35, providing a benchmark for relative valuation. IGC Pharma Inc Corp (IGC.A) exhibits a P/S ratio of 30.54, which is 86.76% above the industry average. Given its robust revenue growth of -53.64%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IGC
1Y
3Y
5Y
Market capitalization of IGC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IGC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IGC currently overvalued or undervalued?
IGC Pharma Inc (IGC) is now in the Overvalued zone, suggesting that its current forward PS ratio of 30.54 is considered Overvalued compared with the five-year average of -1.62. The fair price of IGC Pharma Inc (IGC) is between 0.16 to 0.27 according to relative valuation methord. Compared to the current price of 0.30 USD , IGC Pharma Inc is Overvalued By 11.14% .
What is IGC Pharma Inc (IGC) fair value?
IGC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IGC Pharma Inc (IGC) is between 0.16 to 0.27 according to relative valuation methord.
How does IGC's valuation metrics compare to the industry average?
The average P/S ratio for IGC's competitors is 16.35, providing a benchmark for relative valuation. IGC Pharma Inc Corp (IGC) exhibits a P/S ratio of 30.54, which is 86.76% above the industry average. Given its robust revenue growth of -53.64%, this premium appears unsustainable.
What is the current P/B ratio for IGC Pharma Inc (IGC) as of Jan 09 2026?
As of Jan 09 2026, IGC Pharma Inc (IGC) has a P/B ratio of 3.31. This indicates that the market values IGC at 3.31 times its book value.
What is the current FCF Yield for IGC Pharma Inc (IGC) as of Jan 09 2026?
As of Jan 09 2026, IGC Pharma Inc (IGC) has a FCF Yield of -20.82%. This means that for every dollar of IGC Pharma Inc’s market capitalization, the company generates -20.82 cents in free cash flow.
What is the current Forward P/E ratio for IGC Pharma Inc (IGC) as of Jan 09 2026?
As of Jan 09 2026, IGC Pharma Inc (IGC) has a Forward P/E ratio of -3.64. This means the market is willing to pay $-3.64 for every dollar of IGC Pharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IGC Pharma Inc (IGC) as of Jan 09 2026?
As of Jan 09 2026, IGC Pharma Inc (IGC) has a Forward P/S ratio of 30.54. This means the market is valuing IGC at $30.54 for every dollar of expected revenue over the next 12 months.